PTC Therapeutics Inc (NAS:PTCT)
$ 36.53 3.23 (9.7%) Market Cap: 2.80 Bil Enterprise Value: 2.34 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 74/100

PTC Therapeutics Inc at Barclays Global Healthcare Conference Transcript

Mar 14, 2019 / 06:05PM GMT
Release Date Price: $35.23 (+0.51%)
Gena Wang
Barclays Bank PLC, Research Division - Research Analyst

Good afternoon, everyone. My name is Gena Wang, I'm a mid-cap biotech analyst at Barclays. It is my great pleasure to introduce our next speaker, Stuart Peltz, Chief Executive Officer of PTCT; and also with us, we also have Marcio Souza, Chief Operating Officer, with us for the Q&A discussion.

Stuart W. Peltz
PTC Therapeutics, Inc. - Co-Founder, CEO & Executive Director

Can you hear me? Great. Well, thank you -- thanks for the introduction and the invitation to be here. We're PTC Therapeutics, I'm Stuart Peltz. I will be talking about some forward-looking statements and I suggest that you look at our findings.

So I'll go through a little bit of 2018, I'll just put these up.

My goal here is to give us time to have questions and answers to things that you have, but I wanted to start out and just say, obviously 2018 was truly a transformational year for PTC. Our DMD franchise did quite well and was within guidance. We able to expand Translarna's availability by getting

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot